97275 ⎘
Immunoglobulins specific features characterized by immunoglobulin fragments; Constant or Fc region; Isotype CH1 domain
Heterodimeric antibodies that bind CD3 and tumor antigens
#302METHOD FOR THE EXPRESSION OF AN ANTIBODY-MULTIMER-FUSION
#303Anti-MET antibodies and uses thereof
#304Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
#305CHIMERIC RECEPTOR THAT RECOGNIZES ENGINEERED SITE IN ANTIBODY
#306Anti-PD1 and anti-CTLA4 antibodies
#307MULTISPECIFIC ANTIGEN BINDING PROTEINS
#308Humanized anti-VEGF antibody Fab fragment and use thereof
#309FAB Molecules with a Rodent Hinge Region and a Non-Rodent CH1 Region
#310CDCP1-TARGETED THERAPIES
#311Anti-CD28 compositions
#312AFFINITY CHROMATOGRAPHY PURIFICATION WITH LOW CONDUCTIVITY WASH BUFFER
#313ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION
#314ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#315MODIFIED FC FRAGMENT, ANTIBODY COMPRISING SAME, AND APPLICATION THEREOF
#316Anti-CD28 compositions
#317HEAVY CHAIN ONLY ANTIBODIES TO PDGF
#318Anti-glyco-MUC1 antibodies and their uses
#319Site-specific antibody-drug conjugation through glycoengineering
#320ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
#321GLYCOENGINEERED ANTIBODY DRUG CONJUGATES
#322C-terminal lysine conjugated immunoglobulins
#323BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#324Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease
#325COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4
#326MULTISPECIFIC ANTIGEN BINDING PROTEINS CAPABLE OF BINDING CD19 AND CD3, AND USE THEREOF
#327ANTIBODY CONSTANT REGION VARIANT
#328IGG FC Variants for Veterinary Use
#329TETRAVALENT MULTISPECIFIC ANTIBODIES
#330Heterodimeric antibodies that bind CD3 and tumor antigens
#331Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof
#332THERAPEUTIC MULTISPECIFIC POLYPEPTIDES ACTIVATED BY POLYPEPTIDE CHAIN EXCHANGE
#333ANTIBODIES MODIFIED FOR TRANSGLUTAMINASE CONJUGATION, CONJUGATES THEREOF, AND METHODS AND USES
#334BCMA antibodies and use of same to treat cancer and immunological disorders
#335Anti-ETEC adhesin protein antibodies and methods of use
#336Agonistic CD28 antigen binding molecules targeting Her2
#337ENGINEERED IGA ANTIBODIES AND METHODS OF USE
#338Anti-Met fab-Fc for the treatment of a tumor and/or metastasis
#339Preparation and use of anti-MET-and-RON bispecific antibody and antibody-drug conjugate thereof
#340Anti-Siglec-5 antibodies and methods of use thereof
#341STEREOTYPIC NEUTRALIZING VH CLONOTYPES AGAINST SARS-COV-2 RBD IN COVID-19 PATIENTS AND THE HEALTHY POPULATION
#342PROTEASE CLEAVABLE BISPECIFIC ANTIBODIES AND USES THEREOF
#343Engineered IGA antibodies and methods of use
#344Bispecific antibody which binds to CD40 and EpCAM
#345Antibodies against SARS-CoV-2 and methods of using the same
#346Antigen-Binding Polypeptide Constructs Comprising Kappa and Lambda Light Chains and Uses Thereof
#347NON-HUMAN ANIMALS THAT SELECT FOR LIGHT CHAIN VARIABLE REGIONS THAT BIND ANTIGEN
#348MODIFIED ANTIBODIES CONTAINING MODIFIED IGG2 DOMAINS WHICH ELICIT AGONIST OR ANTAGONISTIC PROPERTIES AND USE THEREOF
#349Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
#350METHODS FOR TREATING OCULAR DISEASES
#351METHODS AND REAGENT FOR ANALYSING NUCLEIC ACIDS FROM INDIVIDUAL CELLS
#352HEAVY CHAIN ONLY ANTIBODIES TO ANG-2
#353ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#354ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#355Anti-RSV monoclonal antibody formulation
#356MULTISPECIFIC ANTIBODIES
#357BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#358BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
#359CD3-targeting and DLL3-targeting multispecific antigen-binding molecules and uses thereof
#360BISPECIFIC ANTIGEN BINDING MOLECULES WITH TRIVALENT BINDING TO CD40
#361PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#362Antibody molecule-drug conjugates and uses thereof
#363PROTEINS BINDING NKG2D, CD16, AND EGFR, CCR4, OR PD-L1
#364Antibodies against SARS-CoV-2 and methods of using the same
#365BISPECIFIC ANTIBODIES
#366Universal T cells and the method of use thereof
#367Antibody/T-cell receptor chimeric constructs and uses thereof
#368MULTISPECIFIC MOLECULES THAT BIND TO MYELOPROLIFERATIVE LEUKEMIA (MPL) PROTEIN AND USES THEREOF
#369Multi-specific molecules
#370LAG-3-binding molecules and methods of use thereof
#371Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#372Methods of using bispecific antigen-binding constructs targeting HER2
#373High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
#374ANTIBODY HALF-MOLECULE, AND METHOD FOR INHIBITING HOMODIMER FORMATION OF ANTIBODY HALF-MOLECULE
#375Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies
#376TRIVALENT TRISPECIFIC ANTIBODY CONSTRUCTS
#377Sodium channel inhibitors
#378Lysine conjugated immunoglobulins
#379NOVEL ANTIBODY FORMAT
#380FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION
#381Antibodies to CD40 with enhanced agonist activity
#382CD19 binding molecules and uses thereof
#383METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELLS BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION
#384Immunomodulatory fusion proteins
#385HETERODIMERIC PROTEINS
#386Nucleic acids encoding an anti-CD154 antibody comprising E269R and K322A mutations
#387N-terminal scFv multispecific binding molecules
#388Engineered IGA antibodies and methods of use
#389Engineered IgA antibodies and methods of use
#390Bispecific antibody and uses thereof
#391COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF
#392A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION
#393Antibody with non-natural amino acid introduced therein
#394Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
#395Heterodimeric antibodies that bind CD3 and tumor antigens
#396FIXaxFX bispecific antibody with common light chain
#397Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
#398Chimeric antibody/T-cell receptor constructs and uses thereof
#399CL and/or CH1 mutated antibodies for drug conjugation
#400Autoimmune suppressor and application thereof
#401Combination of anti-HGFR antibody and HEGFR for the treatment of a tumor and/or metastasis
#402IgG bispecific antibodies and processes for preparation
#403VARIANT DOMAINS FOR MULTIMERIZING PROTEINS AND SEPARATION THEREOF
#404Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
#405METHOD FOR SELECTING ANTIBODIES WITH MODIFIED FCRN INTERACTION
#406Multispecific Antibodies
#407Antigen binding molecule formats
#408Multi-Specific Molecules
#409Serpin fusion polypeptides and methods of use thereof
#410HER2-targeting antigen binding molecules comprising 4-1BBL
#411ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM)
#412Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof
#413NUCLEIC ACID MOLECULES AND APPLICATIONS THEREOF IN PREPARING HUMAN SINGLE-DOMAIN ANTIBODY
#414Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
#415Methods of treating neutorpenia using G-CSF protein complex
#416GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
#417Serpin fusion polypeptides and methods of use thereof
#418Monoclonal antibody specifically binding to human plasmalemma vesicle-associated protein PV-1, preparation and use thereof
#419Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
#420Genetic engineering of non-human animals for the production of chimeric antibodies
#421GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
#422Genetic engineering of non-human animals for the production of chimeric antibodies
#423Trispecific binding proteins, methods, and uses thereof
#424Method for generating multispecific antibodies from monospecific antibodies
#425Combination therapy with targeted OX40 agonists
#426Multispecific antigens binding fragments and multispecific antibodies
#427Genetic engineering of non-human animals for the production of chimeric antibodies
#428Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
#429MULTISPECIFIC MOLECULES AND USES THEREOF
#430IgG epitope and applications thereof as a drug target
#431ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
#432Genetically modified non-human animals and methods for producing heavy chain-only antibodies
#433Anti-RSV monoclonal antibody formulation
#434MULTISPECIFIC ANTIGEN BINDING PROTEINS
#435Assembly of bispecific antibodies
#436VISTA antigen-binding molecules
#437Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein
#438HER3 antigen-binding molecules
#439Periplasmic fusion proteins
#440Multivalent Antigen-Binding Proteins
#441Stable multispecific antibodies
#442Anti-CD3 antibodies and methods of use
#443Anti-CD3 antibodies and methods of use
#444ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#445ANTIGEN BINDING PROTEINS
#446Bispecific HER2 antibodies and methods of use
#447Anti-GD2 antibody
#448Bispecific CD3/CD19 polypeptide complexes
#449LONG ACTING PROTEIN COMPLEX HAVING AN ENHANCED EFFICIENCY
#450Bispecific antigen binding molecule for a costimulatory TNF receptor
#451PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#452Monoclonal antibody antagonizing and inhibiting the binding of human PD-1 antigen to its ligand, preparation method therefor and application thereof
#453Stable protein solution formulation containing high concentration of an anti-VEGF antibody
#454ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#455Multispecific binding proteins with mutant fab domains
#456PseudoFab-based multispecific binding proteins
#457Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer
#458Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
#459BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#460PROTEINS BINDING NKG2D, CD16, AND EGFR, HLA-E, CCR4, OR PD-L1
#461Single chain VH and heavy chain antibodies
#462Heterodimeric antibodies that bind CD3 and CD38
#463FIXaxFX bispecific antibody with common light chain
#464Cell engaging binding molecules
#465Genetic engineering of non-human animals for the production of chimeric antibodies
#466Genetic engineering of non-human animals for the production of chimeric antibodies
#467Heterodimerizing Ig domains
#468FABS-IN-TANDEM IMMUNOGLOBULIN AND USES THEREOF
#469Asymmetric multispecific antibodies
#470Anti-BCMA heavy chain-only antibodies
#471Antibodies of the class IGG4
#472MONOVALENT AND DIVALENT BINDING PROTEINS
#473Hyperglycosylated binding polypeptides
#474Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
#475BISPECIFIC ANTIBODIES
#476Heavy chain only antibodies to PDGF
#477Methods and antibody compositions for tumor treatment
#478Antibody/T-cell receptor chimeric constructs and uses thereof
#479ANTIBODY HEAVY CHAIN VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR
#480ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN
#481Protein complex by use of a specific site of an immunoglobulin fragment for linkage
#482Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#483Antibody variable domains and antibody constructs
#484TUMOR ANTIGEN PRESENTATION INDUCER CONSTRUCTS AND USES THEREOF
#485Binding molecules that bind CD137 and PD-L1
#486PURIFICATION OF HETERO-DIMERIC IMMUNOGLOBULINS
#487C-terminal lysine conjugated immunoglobulins
#488BCMA antibodies and use of same to treat cancer and immunological disorders
#489Chimeric transmembrane proteins and uses thereof
#490MODIFIED CK AND CH1 DOMAINS
#491Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer
#492Engineered heterodimeric proteins
#493Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#494MONOMERIC HUMAN IGG1 FC AND BISPECIFIC ANTIBODIES
#495Multivalent antibody
#496Fab molecules with a rodent hinge region and a non-rodent CH1 region
#497Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
#498Cell engaging binding molecules
#499Multi-Specific Molecules
#500Polypeptide linker for preparing multispecific antibodies
#501MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES
#502Anti-human VISTA antibodies and use thereof
#503Anti-MET antibodies and uses thereof
#504Antibody agents specific for human CD19 and uses thereof
#505Cell engaging binding molecules
#506Cell engaging binding molecules
#507MODIFIED ANTIGEN-BINDING FAB FRAGMENTS AND ANTIGEN-BINDING MOLECULES COMPRISING THE SAME
#508Methods for producing fabs and IgG bispecific antibodies
#509BISPECIFIC ANTIBODY BINDING TO HUMAN CD19 AND CD3
#510POLYPEPTIDE VARIANTS AND USES THEREOF
#511Anti-PD1 and anti-CTLA4 antibodies
#512Recombinant polypeptide production methods
#513Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
#514Genetically modified non-human animals and methods for producing heavy chain-only antibodies
#515Mixtures of antibodies
#516Heavy chain only antibodies to ANG-2
#517Antibody/T-cell receptor chimeric constructs and uses thereof
#518Site-specific antibody-drug conjugation through glycoengineering
#519Single-domain antibodies and variants thereof against CTLA-4
#520Antibodies with reduced binding to process impurities
#521TRANSGENIC NON-HUMAN ANIMALS PRODUCING MODIFIED HEAVY CHAIN-ONLY ANTIBODIES
#522Anti-PD-L1 antibodies and methods of use
#523NOVEL ANTIBODY FORMAT
#524PAC1 antibodies and uses thereof
#525Methods for producing Fabs and bi-specific antibodies
#526BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#527ANTIBODY CONSTANT REGION VARIANT
#528Heterodimeric antibodies that bind CD3 and tumor antigens
#529Sequence symmetric modified IgG4 bispecific antibodies
#530Cysteine-optimized stradomers
#531ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
#532Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure
#533Monovalent Asymmetric Tandem Fab Bispecific Antibodies
#534Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
#535METHOD FOR PRODUCING ANTIBODY FRAGMENT
#536Cytosol-penetrating antibody and use thereof
#537Dual specificity antibody fusions
#538Antibody with non-natural amino acid introduced therein
#539Anti-glyco-MUC1 antibodies and their uses
#540Anti-CD3 antibodies and methods of use
#541Antibody fab and Fc variants
#542LAG-3-binding molecules and methods of use thereof
#543Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
#544NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE
#545IMMUNOGLOBULIN VARIANTS AND USES THEREOF
#546Antibodies against CD73 and uses thereof
#547Glycoengineered antibody drug conjugates
#548ANTIBODIES AGAINST CD73 AND USES THEREOF
#549Multispecific NK engager protein
#550Multispecific NK engager protein
#551METHODS OF SCREENING FOR MULTISPECIFIC ANTIBODIES
#552Anti-cancer antibodies with reduced complement fixation
#553Bispecific antibodies having constant region mutations and uses therefor
#554Antibody/T-cell receptor chimeric constructs and uses thereof
#555Anti-CD3 antibodies and methods of use
#556PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF
#557IG1 AND THE THERAPEUTIC USE THEREOF
#558Methods for generating bispecific functional agents
#559Antibodies comprising modified heavy constant regions
#560Pyrrolobenzodiazepine antibody drug conjugates and methods of use
#561Bispecific antibodies specifically binding to PD1 and LAG3
#562Protein complex by use of a specific site of an immunoglobulin fragment for linkage
#563Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof
#564Methods for producing fabs and bi-specific antibodies
#565Antigen-Binding Protein Directed Against Epitope in the CH1 Domain of Human IgG Antibodies
#566Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
#567Methods for treating ocular diseases with brolucizumab
#568Heterodimeric antibodies that bind CD3 and tumor antigens
#569Anti-RSV monoclonal antibody formulation
#570Non-human animals that select for light chain variable regions that bind antigen
#571Dual PDGF/VEGF antagonists
#572TETRAVALENT BISPECIFIC AND TETRASPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
#573Antibody fragments, compositions and uses thereof
#574Refolding process for antibody's fragments
#575Heterodimeric antibodies that bind CD3 and tumor antigens
#576Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
#577Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
#578AFFINITY CHROMATOGRAPHY PURIFICATION WITH LOW CONDUCTIVITY WASH BUFFER
#579Pyrrolobenzodiazepine antibody drug conjugates and methods of use
#580Bispecific antibodies
#581Serpin fusion polypeptides and methods of use thereof
#582Multispecific antigen-binding proteins
#583Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers
#584Assembly of bispecific antibodies
#585Long-acting insulin or insulin analogue conjugate
#586Antibodies
#587Antibody agents specific for human CD19 and uses thereof
#588Immunomodulatory fusion proteins
#589Antibodies against CD73 and uses thereof
#590Dual specificity antibody fusions
#591Bispecific T cell activating antigen binding molecules
#592Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
#593Bispecific multivalent fusion proteins
#594Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
#595CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF
#596OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
#597Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Use
#598Fc containing polypeptides with altered glycosylation and reduced effector function
#599ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES
#600Antibody/T-cell receptor chimeric constructs and uses thereof